Apr 2 |
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
|
Apr 2 |
Q4 2023 Jaguar Health Inc Earnings Call
|
Apr 1 |
Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript
|
Apr 1 |
Jaguar Health GAAP EPS of -$1.79, revenue of $9.76M
|
Apr 1 |
Jaguar Health Reports 2023 Financial Results
|
Apr 1 |
Earnings Scheduled For April 1, 2024
|
Mar 27 |
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
|
Mar 20 |
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
|
Feb 23 |
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
|
Feb 15 |
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
|